Office of Commercialization and Economic Development
Office of Technology Commercialization

Gamma Secretase Inhibitors Attenuate Vascular Malformations

Technology #16-0192

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Julie Blatt
Managed By
Jackie Quay
Director 919.966.3929
Patent Protection
Provisional Patent Application Filed

Gamma secretase inhibitors (GSI) have been determined to attenuate vascular malformations by inhibiting NOTCH expression in endothelial cells.  Vascular malformations are developmental abnormalities of venous, arterial, capillary or lymphatic vessels which have significant morbidities such as pain, infection, pulmonary emboli, bleeding and even death. There is growing interest in medical management of vascular malformations, however existing treatments often do not result in complete lesion resolution and do not produce permanent results, thus there is a significant need for alternative therapies. The use of GSIs can provide an alternative and potent treatment for vascular formations.

Related Publications: